Dear Sir, Hypercoagulability is not a rare finding in nephrotic patients under the administration of adrenal steroids. The deposition of fibri-nogen in the renal biopsy specimen and the increase in plasma and/or urinary fibrinogen degradation products are often noted during the course of nephrosis. In the last 2 years we have seen 3 nephrotic patients with thrombogenic complications. All of them exhibited high concentrations of plasma lipoprotein(a) [Lp(a)], even when they were in the remission stage. Lp(a) is a cholesterol-rich plasma li-poprotein containing aρo(a) and apo B-100, and is said to be associated with the development of atherosclerosis [1]. It is also known to have thrombogenic properties because it has close structural homology with plasminogen [2]. Several investigators have demonstrated that Lp(a) is an independent risk factor for coronary heart disease (CHD) [3]. As reported by Armstrong et al. [4], when the plasma level of Lp(a) is above 30 mg/dl the risk for CHD increases two fold. We have measured plasma Lp(a) levels in patients with nephrotic syndrome, and investigated whether the increase in Lp(a) predicts the risk of thrombogenic complications in nephrotic patients under the adrenal steroid therapy. Plasma samples were taken from 32 normal volunteers, 20 nephrotic patients without thrombogenic complications (9 of them were in the remission stage), 1 nephrotic patient with acute myocardial infarction (case 2), and 2 nephrotic patients with cerebral infarction (cases 1 and 3). The plasma Lp(a) level was measured by the enzyme-linked immunoas-say kits (Biopool AB) [5]. Low density lipo-protein (LDL) cholesterol was calculated using the Friedwald approximation. As shown in table 1, Lp(a) and LDL cholesterol levels Table 1 . Plasma Lp(a) and LDL cholesterol levels in nephrotic patients and normal volunteers (mean ± SD) were significantly elevated in nephrotic patients. These values were more increased in the nephrotic stage. The plasma Lp(a) levels of 3 complicated patients remained above 45 mg/dl even in the remission stage. Our results suggest that plasma Lp(a) may predict the risk of thrombogenic complications in nephrosis. Thereby, we propose that the simultaneous use of anticoagulant drugs should be 
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